Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

British Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2002, Pages 372-377

  Snell, Paul ^a   Oo, Charles ^b   Dorr, Al ^c   Barrett, Joanne ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

^c XIQ Coordination Inc   (United States)

Author keywords

Antacids; Influenza; Neuraminidase inhibitor; Oseltamivir; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; CALCIUM CARBONATE; DRUG METABOLITE; OSELTAMIVIR; PRODRUG; SIALIDASE INHIBITOR; TITRALAC; VIRUS ENZYME;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFLUENZA VIRUS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTACIDS; ANTIVIRAL AGENTS; CALCIUM CARBONATE; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA, HUMAN; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; OSELTAMIVIR; PRODRUGS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0036430043     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01678.x     Document Type: Article

References (10)

1. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-484.
2. Oo C, Barrett J, Hill G, et al. Clinical pharmacokinetics and dose recommendation of oseltamivir suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3: 229-236.
3. Maton PN, Burton ME. Antacids revisited. A review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855-870.
4. Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404-434.
5. Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977; 2: 269-280.
6. Reynolds JC. The clinical importance of drug interactions with anti-ulcer therapy. J Clin Gastroenterol 1990; 12 (Suppl 2): S54-S63.
7. Gugler AH. Effects of antacids on the clinical pharmacokinetics of drugs: An update. Clin Pharmacokinet 1990; 18: 210-219.
8. Lomaestro BM, Bailie GR. Absorption interactions with flouroquinolones. Drug Safety 1995; 12: 314-333.
9. Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B 2000; 745: 373-388.
10. D'Arcy PF, McElnay JC. Drug-antacid interactions: Assessment of clinical importance. Drug Intell Clin Pharm 1987; 21: 607-617.